CJC-1295 vs Sermorelin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, CJC-1295 or Sermorelin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between CJC-1295 and Sermorelin?
Sermorelin's 29-amino acid sequence is GHRH(1-29) with a brief (~10-20 minute) half-life, producing physiological GH pulses. CJC-1295 (with DAC) has an ~8-day half-life producing continuous GH elevation - a fundamentally different pharmacodynamic profile.
Evidence Comparison
Sermorelin has FDA-approved status (for pediatric GH deficiency and diagnostic use) and 6-month RCT data in elderly adults (Walker et al. 1997). CJC-1295 has Phase 2 data in healthy adults. Sermorelin's manufacturer withdrew it commercially in 2008; it now exists only as compounded product.
Evidence Context Favoring CJC-1295
Research requiring a longer-acting GH secretagogue or sustained IGF-1 elevation.
Evidence Context Favoring Sermorelin
Research requiring FDA-pedigree human GH stimulation data, or contexts where physiological pulsatile GH elevation is important.
Side-by-Side Snapshot
| Evidence grade | CJC-1295: Level B Sermorelin: Level B |
|---|---|
| Research status | CJC-1295: Phase 2 Sermorelin: Historical FDA Approval |
| Primary category | CJC-1295: Growth Hormone Sermorelin: Growth Hormone |
| Cited studies | CJC-1295: 1 Sermorelin: 2 |